Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the market average. Buying under-rated businesses is one path to excess returns. For example, long term QIAGEN N.V. (NYSE:QGEN) shareholders have enjoyed a 94% share price rise over the last half decade, well in excess of the market return of around 47% (not including dividends). On the other hand, the more recent gains haven’t been so impressive, with shareholders gaining just 27%.


The wisdom of Warren Buffett reflects a value-based philosophy about investing that says investors are buying shares in a business, and encourages strategic thinking about investment time horizon. Before placing a buy order for a stock, a great question we can ask is whether we would still be comfortable making the investment if we couldn’t sell it for many years?


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”), a late clinical-stage biopharmaceutical company focused on the global immunology market, today announced the appointment of Mr. Peter Greenleaf as Chief Executive Officer and as a Director on the Aurinia Board. The Company also announced the elevation of George M. Milne, Jr., Ph.D. to Chairman of the Board of Directors. Dr. Richard M. Glickman, who previously announced his plans to retire on November 6, 2018, will step down from his role as Chairman and CEO concurrent with Mr. Greenleaf’s appointment on April 29, 2019, and will remain an advisor to the Company for a period of 12 months.


April 17, 2019 @ 4:30 PM – 7:00 PM

Join Mtech’s Biotechnology Research and Education Program (BREP) for a special launch event at the University of Maryland IBBR Building in Rockville on April 17th, 2019. Learn about this new industry-relevant new course and enjoy an evening of traditional BioBuzz networking with others in the regional biotech ecosystem.


The 5th annual Biohealth Capital Region (BHCR) Forum was held on April 8th and 9th at AstraZeneca in Gaithersburg, MD. Biotech and life science executives and expert speakers from industry, academia, healthcare, government, finance and real estate development, among others, converged to discuss the BHCR’s path forward to becoming a top three U.S. biotech cluster by 2023.

Rich Bendis, CEO of BioHealth Innovation, and host of the forum welcomed the 1,200 registered attendees (double the number of the first forum) with the annual update on the region’s progress towards that goal.  After moving up one spot in 2018 to number four, according to GEN Biotechnology’s annual rankings, the BHCR is building momentum fueled by record VC investment, new lab space and multiple new companies moving into the region.


Baltimore is brimming with entrepreneurial talent. A new generation of CEOs and inventors are emerging right here in Baltimore with companies that are revolutionizing the life science & healthcare industries. The local community of universities and investors, coupled with the broader assets of the BioHealth Capital Region, has provided a lush ecosystem for innovators to take their ideas to the next level.


Alexandria Real Estate Equities, Inc. (NYSE:  ARE), an urban office REIT uniquely focused on collaborative life science and technology campuses in AAA innovation clusters, today celebrates the inaugural member class of seed- and early-stage life science companies at the Alexandria LaunchLabs® – Cambridge with a highly curated Grand Opening event. The 20,000 RSF space, located at the Alexandria Center® at One Kendall Square, is now home to 13 new member companies rigorously selected from a deep pool of applicants based on the quality of their science, leadership teams and business strategies. Alexandria also offers a unique opportunity to access capital through the Alexandria Seed Capital Platform, which is led by Alexandria Venture Investments and supported by a preeminent group of member biopharmaceutical and venture entities. The Alexandria Seed Capital Platform recently closed on its first investment in a Cambridge‑based company.


Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced that its Board of Directors has approved a one-for-twelve (1-for-12) reverse stock split of its common stock that will become effective Friday, April 12, 2019, upon the filing of a Certificate of Amendment to its Certificate of Incorporation with the Secretary of the State of Delaware. Beginning on April 12, 2019, Rexahn’s common stock will trade on NYSE American on a reverse split-adjusted basis under the new CUSIP number 761640309.

Floreo 2019 crab trap image

– Winning company focused on learning solutions for those with Autism.

Other finalists presented innovative technologies related to Multiple Sclerosis, Spine Alignment, TBI and Oncolytic Immunotherapeutics 

Competition sponsored by Wilson Sonsini Goodrich & Rosati held during 2019 BioHealth Capital Region Forum –

Judges of the 2019 Crab Trap competition present Floreo Inc. CEO and Co-Founder, Vijay Ravindran their award 

ROCKVILLE, MARYLAND, April 9, 2018 – Floreo Inc., an early stage startup founded in 2016 which is leveraging the power of virtual reality to deliver immersive, fun, and affordable lessons for children and adults with autism spectrum disorder (ASD), was chosen from five finalists as the firm with the most commercial potential at the 4th Annual Crab Trap Competition. This year’s judges included industry leaders John Rubin of JP Morgan Private Bank, Charles J. Andres of Wilson Sonsino Goodrich & Rosati’s, Raghav Bhargava  of New Enterprise Associates (NEA), Ethel Rubin of NIH/BHI, John Trainer of AstraZeneca, and Norm Marcus, MD. Of Sanderling Ventures.

The Judges were impressed with Floreo’s CEO and Co-Founder, Vijay Ravindran, presentation of his company’s technology which was inspired by his autistic son’s reaction to virtual reality. Floreo’s library of lessions are currently used in schools, therapy, and homes while providing a supervising adult the opportunity to monitor and track the learner’s progress. Floreo joins previous Crab Trap winners Galen Robotics (2018), LifeSprout (2017) and Sonavex (2016).


UMBC’s underdog basketball team did not pull off another stunning upset this year, but the school’s scientists continue to conquer the STEM world.

Facebook founder Mark Zuckerberg and his wife, Dr. Priscilla Chan, just announced that they will put part of their enormous wealth behind an effort to spread the University of Maryland, Baltimore County’s successful STEM honors program to two University of California colleges.


Johnson & Johnson Innovation LLC and Children’s National Health System (Children’s National) today announced a collaboration to launch JLABS @ Washington, DC, a 32,000-square foot facility to be located at the new Children’s National Research and Innovation Campus in Washington, D.C. This Children’s National expansion is set on a nearly 12-acre portion of the former Walter Reed Army Medical Center campus in the nation’s capital. The co-location of the Research and Innovation Campus with key partners in the areas of public health research, innovation and incubator space is critical to accelerating the translation of potential breakthrough discoveries into new treatments and technologies. The JLABS @ Washington, DC site will be open to pharmaceutical, medical device, consumer and health technology companies that are aiming to advance the development of new drugs, medical devices, precision diagnostics and health technologies, including applications in pediatrics.


You’re about to go under the knife and the anesthesia is taking hold. Is it better to look up and see a robot surgeon with autonomous capabilities looming over you, or an old-fashioned human doctor?


When: Wednesday, April 10, 2019 8:00 a.m. to 9:30 a.m. EST

Where: Hosick Lecture Hall655 West Baltimore StreetBressler Research Bldg.Baltimore, MD  21201United States

This Baltimore Meetup is free for members and students, and members may bring up to two guests at the member price (free). If you're new to WIB and interested in checking it out before becoming a member, please reach out via This email address is being protected from spambots. You need JavaScript enabled to view it.


Six panelists share their expertise on social media and personal interactions, with a facilitator